As to colorectal cancer, it has been proven that aberrant overexpression of antiapoptotic BCL-2 family proteins is closely linked to colorectal tumorigenesis, poor prognosis, and drug resistance, thus highlighting the potential of drugs targeting antiapoptotic BCL-2 proteins for colorectal cancer therapy [8,9,10]. The gene discussed is BCL2; the disease is colorectal cancer.